Merck's Keytruda got a green light from the U.K.'s cost-effectiveness gatekeeper to treat patients with advanced skin cancer, chalking up another victory as it picks up steam in its head-to-head battle with Bristol-Myers Squibb's Opdivo.
Gilead and AbbVie may be dominating the hep C field with their next-gen combo treatments, but that doesn't mean there's no room for other companies to sneak in.
Bristol-Myers Squibb is the latest Big Pharma to pay up for bribery in China. The U.S.-based drugmaker agreed to a $14.7 million settlement with the Securities and Exchange Commission, to wrap up charges that its Chinese joint venture shelled out cash and other incentives to boost scripts for its drugs.
Bristol-Myers Squibb continued its immuno-therapy march today with a combo approval in melanoma. The pairing of its older med Yervoy and new PD-1 cancer-fighter Opdivo won the FDA's green light for patients with advanced melanoma and a particular genetic variation.
The deal makes ZS Bristol's primary vendor in the sector, allowing the Big Pharma to trim the list of vendors with which it works to analyze commercial data.
Checkpoint inhibitors Opdivo from Bristol-Myers Squibb and Keytruda from Merck are racing to rack up oncology indications in a range of cancer areas. But with Opdivo vaulting toward a kidney cancer approval, the collective group is about to claim its "first casualty" of the "paradigm shift" toward immuno-oncology drugs, in the words of Bernstein analyst Tim Anderson.
Last July, Bristol-Myers Squibb put an early end to a late-stage study that showed its immunotherapy drug, Opdivo, looked good in patients with advanced kidney cancer. And now, it's one step closer to landing a nod in that population.
More than 80 Bristol-Myers Squibb employees on 6 teams saddle up Thursday for a cancer-fighting cycling campaign. Amid the company's immuno-oncology push in R&D and sales, the oncology employees are raising money for the national organization Stand Up to Cancer--and BMS will match their earnings dollar-for-dollar up to $500,000. In its second year, the expanded team, up from 53 riders last year, hopes to top $1 million for Stand Up to Cancer.
Bristol Myers-Squibb, a leader among companies at work in immuno-oncology, is pressing for wider use of its lead treatment with new data showing the injected drug could succeed as part of a first-line treatment in lung cancer.
A new drug for blood cancer from Bristol-Myers Squibb and AbbVie is on the fast track to FDA approval, winning a priority review to treat multiple myeloma.